Simultaneous bilateral subtrochanteric fractures following risedronate therapy

Bisphosphonates are the most commonly prescribed drugs for the treatment of osteoporosis, and have been shown to be highly effective in reducing the risk of vertebral and hip fractures [1]. The mechanism of action of bisphosphonates is based on the inhibition of osteoclast function and induction of osteoclast apoptosis. In experimental studies, prolonged suppression of bone turnover has been shown to result in accumulation of microdamage and increased bone fragility [2, 3].